Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Official title

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Study identification

NCT ID

NCT03851445

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 2, Phase 3

Lead sponsor

SWOG Cancer Research Network

Network

Enrollment

10,000 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Feb 5, 2019

Primary completion

Jan 27, 2029

Completion

Jan 27, 2029

Last update posted

Dec 4, 2025

2019 – 2029

United States locations

U.S. sites

1201

U.S. states

51

U.S. cities

796

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.